SCOTTSDALE, Ariz., Feb. 27, 2012 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues of approximately $180.7 million for the three months ended December 31, 2011, compared to revenues of approximately $179.7 million for the three months ended December 31, 2010, which represents an increase of approximately $1.0 million, or approximately 0.6%. This increase is due primarily to increased demand for DYSPORT®, the RESTYLANE® franchise, VANOS® and ZIANA®, and includes the impact of increased sales reserves in the fourth quarter of 2011 associated with the Company’s previously announced managed care strategy, and the discontinuation of TRIAZ® and PLEXION® earlier in the year.
